| Literature DB >> 34822103 |
Motoko Morishima1, Tomonari Kiriyama2, Yasuo Miyagi1, Toshiaki Otsuka3,4, Yoshimitsu Fukushima2, Shin-Ichiro Kumita2, Yosuke Ishii5.
Abstract
OBJECTIVE: Myocardial ischemia is known to suppress fatty acid metabolism and favor glucose metabolism. However, changes in myocardial metabolism after coronary revascularization are not fully elucidated.Entities:
Keywords: 123I-BMIPP SPECT; Coronary artery bypass grafting; Myocardial metabolism; Myocardial perfusion imaging; Perfusion–metabolism mismatch
Mesh:
Substances:
Year: 2021 PMID: 34822103 PMCID: PMC8897360 DOI: 10.1007/s12149-021-01696-3
Source DB: PubMed Journal: Ann Nucl Med ISSN: 0914-7187 Impact factor: 2.668
Baseline characteristics of the study population
| Characteristic | All patients ( |
|---|---|
| Pre-operative | |
| Age (years) | 69.9 ± 8.7 |
| Male gender (%) | 34 (89) |
| Hypertension (%) | 30 (79) |
| Diabetes mellitus (%) | 18 (47) |
| Dyslipidemia (%) | 31 (82) |
| Previous MI (%) | 22 (58) |
| Prior PCI (%) | 14 (37) |
| eGFR (ml/min/1.73m2) | 52.1 ± 22.3 |
| Left main disease (%) | 8 (21) |
| Number of disease vessels (%) | |
| 3 | 20 (53) |
| 2 | 15 (39) |
| 1 | 3 (8) |
| SYNTAX score | 25.1 ± 10.1 |
| LVEF (%) | 52.9 ± 17.5 |
| Operative | |
| ACS (%) | 3 (8) |
| On-pump CABG (%) | 3 (8) |
| Number of anastomoses | 3.8 ± 1.5 |
| Number of grafts | 2.6 ± 0.8 |
| IMA (%) | 34 (89) |
| Radial Artery (%) | 7 (18) |
| GEA (%) | 8 (21) |
| Saphenous vein graft (%) | 22 (58) |
Data are mean ± SD or n (%)
SD standard deviation, MI myocardial infarction, PCI percutaneous coronary intervention, eGFR estimated glomerular filtration rate, SYNTAX Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery, LVEF left ventricular ejection fraction, ACS acute coronary syndrome, CABG coronary artery bypass grafting, IMA internal mammary artery, GEA gastroepiploic artery
Fig. 1Changes in SRS (a), SDS (b), BMIPP score (c), and mismatch score (d) from short- to mid-term postoperative period. *P < 0.05, **P < 0.01 vs. the short-term
Fig. 2a At 3 months after CABG. 99mTc-tetrofosmin pharmacological stress perfusion SPECT showed neither ischemia nor infarction. A decreased uptake in the inferior wall, which was more prominent at rest, was considered to be an artifact due to attenuation and/or high abdominal accumulation. In BMIPP SPECT, there was a mild to moderate decrease in anterolateral wall as scored BMIPP score 6 (white arrow). b At 25 months after CABG, anterolateral tracer activity of BMIPP SPECT was recovered. Inferior defect in perfusion SPECT at rest was considered to be an artifact due to high abdominal uptake. A slight posterior defect on stress images was also considered to be an artifact, however, was scored as SDS 2 (white arrowhead)
Fig. 3a At 17 months after CABG. 99mTc-tetrofosmin pharmacological stress perfusion SPECT showed inferoposterior infarction as scored SRS 6 (white arrow head) and no ischemia. In BMIPP SPECT, there was a severe decrease to complete defect in the inferior wall with a perfusion–metabolic mismatch (white arrow) as scored BMIPP score 9. b BMIPP SPECT at 47 months after CABG showed a persistent defect in the inferior wall with a perfusion–metabolic mismatch as scored BMIPP score 8 (white arrow), while a perfusion defect was improved and scored SRS 3 (white arrow head)
Comparison of patient characteristics between persistent mismatch (PM) and non-persistent mismatch (non-PM) groups
| Group PM ( | Group non-PM ( | ||
|---|---|---|---|
| Pre-operative | |||
| Age (years) | 72.1 ± 7.7 | 68.8 ± 9.2 | 0.317 |
| Male gender (%) | 12 (92) | 22 (88) | 1.000 |
| Previous MI (%) | 8 (62) | 14 (56) | 1.000 |
| Prior PCI (%) | 4 (31) | 10 (40) | 0.728 |
| Left main disease (%) | 4 (31) | 4 (16) | 0.407 |
| Hypertension (%) | 9 (69) | 21 (84) | 0.407 |
| Dyslipidemia (%) | 10 (77) | 21 (84) | 0.672 |
| Diabetes mellitus (%) | 6 (46) | 12 (48) | 1.000 |
| eGFR (ml/min/1.73m2) | 41.1 ± 16.8 | 57.8 ± 23.0 | 0.015* |
| Hemodialysis (%) | 1 (8) | 2 (8) | 1.000 |
| COPD (%) | 2 (15) | 5 (20) | 1.000 |
| Three-vessel disease (%) | 8 (62) | 12 (48) | 0.506 |
| SYNTAX score | 30.8 ± 8.3 | 22.1 ± 9.7 | 0.013* |
| Pre-operative LVEF (%) | 46.4 ± 20.2 | 56.2 ± 15.3 | 0.175 |
| Operative | |||
| ACS (%) | 2 (15) | 1 (4) | 0.265 |
| On-pump CABG (%) | 2 (15) | 1 (4) | 0.265 |
| Number of anastomoses | 4.2 ± 1.3 | 3.6 ± 1.6 | 0.345 |
| Number of grafts | 2.5 ± 0.5 | 2.6 ± 1.0 | 0.334 |
| Post-operative medications | |||
| β-Blockers (%) | 13 (100) | 22 (88) | 0.193 |
| Calcium blockers (%) | 4 (31) | 9 (36) | 1.000 |
| ACEI, ARB (%) | 2 (15) | 12 (48) | 0.077 |
| Diuretics (%) | 8 (62) | 9 (36) | 0.133 |
| Anticoagulation drugs (%) | 5 (38) | 6 (24) | 0.457 |
| Statins (%) | 10 (77) | 24 (96) | 0.069 |
Data are mean ± SD or n (%)
SD standard deviation, MI myocardial infarction, PCI percutaneous coronary intervention, eGFR estimated glomerular filtration rate, COPD chronic obstructive pulmonary disease, SYNTAX Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery, LVEF left ventricular ejection fraction, ACS acute coronary syndrome, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker
*P < 0.05
Univariable and multivariable analyses of clinical variables for persistent perfusion–metabolism mismatch
| Characteristics | Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Pre-operative | ||||||
| Age (years) | 1.047 | 0.965–1.135 | 0.272 | – | ||
| Male gender | 1.636 | 0.153–17.504 | 0.684 | – | ||
| Previous MI | 1.257 | 0.320–4.939 | 0.743 | – | ||
| Prior PCI | 0.667 | 0.161–2.769 | 0.577 | – | ||
| Left main disease | 2.333 | 0.475–11.451 | 0.297 | – | ||
| HT | 0.429 | 0.087–2.103 | 0.297 | – | ||
| DL | 0.635 | 0.119–3.392 | 0.595 | – | ||
| DM | 0.929 | 0.242–3.558 | 0.914 | – | ||
| eGFR | 0.962 | 0.927–0.998 | 0.038* | 0.941 | 0.898–0.985 | 0.010* |
| Three-vessel disease | 1.733 | 0.443–6.789 | 0.430 | – | ||
| SYNTAX score | 1.100 | 1.017–1.190 | 0.017* | 1.126 | 1.011–1.254 | 0.031* |
| Pre-operative LVEF (%) | 0.967 | 0.928–1.007 | 0.107 | NS | – | – |
| Operative | – | |||||
| ACS (%) | 4.364 | 0.357–53.389 | 0.249 | – | ||
| Number of anastomosis | 1.297 | 0.807–2.084 | 0.283 | – | ||
| Post-operative | ||||||
| SRS score (short-term) | 1.022 | 0.941–1.111 | 0.603 | – | ||
| SDS score (short-term) | 0.929 | 0.719–1.200 | 0.572 | – | ||
| BMIPP score (short-term) | 1.064 | 0.983–1.150 | 0.124 | NS | – | – |
| Mismatch score (short-term) | 1.344 | 1.065–1.695 | 0.013* | 1.377 | 1.003–1.890 | 0.048* |
| Post-operative medications | ||||||
| β-Blockers (%) | NA | |||||
| Calcium blockers (%) | 0.790 | 0.188–3.312 | 0.747 | |||
| ACEI, ARB (%) | 0.197 | 0.036–1.077 | 0.061 | NS | – | – |
| Diuretics (%) | 2.844 | 0.713–11.351 | 0.139 | NS | ||
| Anticoagulation drugs (%) | 1.979 | 0.466–8.404 | 0.355 | |||
| Statins (%) | 0.139 | 0.013–1.501 | 0.104 | NS | ||
MI myocardial infarction, PCI percutaneous coronary intervention, eGFR estimated glomerular filtration rate, SYNTAX Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery, LVEF left ventricular ejection fraction, ACS acute coronary syndrome, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, NA not assessed in the univariable analysis since all patients in Group PM were taking β-blockers, NS not selected in the multivariable analysis
*P < 0.05
Fig. 4a Mismatch score in the short-term postoperative period significantly correlated with SYNTAX score (r = 0.400, P = 0.013). b Mismatch score in the mid-term postoperative period significantly correlated with SYNTAX score (r = 0.472, P = 0.003)
Comparison of LVEF, LVEDVI at rest, and stress, changes in LVEF and cardiac events between persistent mismatch (PM) and non-persistent mismatch (non-PM) groups
| Group PM ( | Group non-PM ( | ||
|---|---|---|---|
| Pre-operative | |||
| LVEF (%) | 46.4 ± 20.2 | 56.2 ± 15.3 | 0.175 |
| Post-operative | |||
| LVEF (short- term) (%) | 54.8 ± 14.1 | 58.2 ± 15.9 | 0.361 |
| LVEF (mid-term) (%) | 55.8 ± 9.56 | 61.4 ± 15.5 | 0.051 |
| ΔLVEF (pre-op to short-term) | 8.4 ± 13 | 2.0 ± 8.2 | 0.156 |
| ΔLVEF (pre-op to mid-term) | 9.5 ± 15 | 5.2 ± 10 | 0.528 |
| ΔLVEF (short to mid-term) | 1.1 ± 12 | 3.2 ± 8.2 | 0.274 |
| Increase ≥ 10% in LVEF (pre-op to short-term) | 6 (46) | 5 (20) | 0.092 |
| Increase ≥ 10% in LVEF (pre-op to mid-term) | 5 (38) | 9 (36) | 0.881 |
| Increase ≥ 10% in LVEF (short to mid-term) | 3 (23) | 6 (24) | 0.949 |
| Stress LVEDVI (short-term) (ml/m2) | 62.7 ± 22.0 | 59.7 ± 23.0 | 0.381 |
| Rest LVEDVI (short-term) (ml/m2) | 58.9 ± 21.7 | 55.6 ± 23.6 | 0.249 |
| Stress LVEDVI (mid-term) (ml/m2) | 61.0 ± 21.4 | 58.4 ± 22.8 | 0.612 |
| Rest LVEDVI (mid-term) (ml/m2) | 57.8 ± 20.0 | 54.9 ± 21.4 | 0.465 |
| ΔStress LVEDVI (ml/m2) | 1.25 ± 11.8 | 1.72 ± 19.8 | 0.747 |
| ΔRest LVEDVI (ml/m2) | 0.711 ± 10.1 | 1.06 ± 19.2 | 0.879 |
| Cardiac events | |||
| Hospitalization for heart failure | 2 (15) | 0 | 0.111 |
| Myocardial infarction | 0 | 0 | |
| Unstable angina | 0 | 0 | |
| Cardiac death | 0 | 0 | |
Data are mean ± SD or n (%)
LVEF left ventricular ejection fraction, LVEDVI left ventricular end-diastolic volume index, pre-op pre-operation